Dr. David Z. Rose is an Associate Professor in the Department of Neurology at USF Health, the Neurology Medical Director, a Neuro-Icu Member, and part of the Critical Care Steering Committee. In this video Dr. Rose discusses the AREST trial known as Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation.
Link to Abstract-
The goal of this study is to see if starting Apixaban earlier than standard of treatment reduces the risk of second stroke in adults with atrial fibrillation.
This is an open label, randomized, active control, parallel-group pilot trial to see if starting APIXABAN at days 0-3 (TIA), days 3-5 (small stroke), and days 7-9 (medium stroke) reduces fatal and/or recurrent stroke/TIA in 120 people who have had a recent (within 48 hours of symptoms) TIA or small to medium ischemic stroke. The subjects will be randomly assigned to one of two treatment arms in a 1:1 ratio (apixaban or warfarin). From screening to monthly follow-up visits, subjects will be observed for a total of 180 days.
The following are the primary outcome measures:
Number of people who had a fatal stroke, recurrent ischaemic stroke, or TIA as a composite endpoint [180-day time frame]
Measures of Secondary Outcomes:
The number of people who had an intracranial hemorrhage as determined by MRI/CT [duration: 180 days]